



**CCS/CTS Canadian Thoracic Society Position Statement on Pulmonary Hypertension**

Panel Member's Relationships with Industry (RWI)

The CCS is committed to preserving the scientific integrity of its Guidelines and Position Statements through transparency and management of relationships with industry (RWI). Panel members must disclose all relationships with industry regardless of relevance to the statement topic (see below). When a potential conflict exists, the affected member must recuse during the formal consensus voting process. For more information on the CCS Guideline Development process, please visit [www.ccs.ca](http://www.ccs.ca).

Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this statement.

Member	Consulting Fees/ Honoraria	Clinical Trials	Other Financial Benefit	Relevance to Statement
<b>Primary Panel</b>				
<b>Lisa Mielniczuk</b>	Actelion, Bayer, Pharmascience, Servier	Bayer	None	
<b>David Langleben</b>	Actelion, Bayer, Northern Therapeutics, PhaseBio, United Therapeutics	Arena, Actelion, Bayer, Northern Therapeutics	None	None
<b>Sanjay Mehta</b>	Actelion/Janssen, Bayer, Natco	Actelion/Janssen, Bellerophon, Eiger, Gilead, Reata, United Therapeutics	None	None
<b>Kim Connelly</b>	Bristol-Myers Squibb, Boehringer Ingelheim, Janssen, Lilly, Merck, Novartis, Servier	Amgen, Boehringer Ingelheim	None	
<b>Nathan Brunner</b>	Bayer, Actelion	Bayer, Actelion	None	
<b>Naushad Hirani</b>	Bayer, Actelion	Bayer, Bellerophon, Gilead, United Therapeutics	None	
<b>Ali Kapasi</b>	Bayer, Boehringer Ingelheim, GlaxoSmithKline, Roche, Actelion	Bayer, Boehringer Ingelheim, Sanofi, Actelion	None	
<b>Secondary Panel</b>				
<b>Stephen Archer</b>	None	None	None	
<b>George Chandy</b>	Bayer, Actelion Pharmaceuticals, Janssen	Bayer, Actelion Pharmaceuticals, Janssen	None	
<b>John Granton</b>	Bayer, Actelion, United Therapeutics (DSMC, Steering, Adjudication committees)	Bayer, Eli Lilly, Pfizer, United Therapeutics, Ikaria, Belleraphron, Eiger, Janssen Pharmaceuticals	None	Lilly, Pfizer, Ikaria, Bayer and Janssen Pharmaceuticals have medication for pulmonary hypertension in market.
<b>Simon Jackson</b>	Bayer	None	None	
<b>Lisa Lee</b>	Actelion Global	None	None	
<b>Jamie Myrah</b>	None	None	None	
<b>Ian Paterson</b>	None	None	None	
<b>Sharon Proudfoot</b>	None	None	None	
<b>Lawrence Rudski</b>	None	None	General Electric - minor shareholder	

Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this statement.

Member	Consulting Fees/ Honoraria	Clinical Trials	Other Financial Benefit	Relevance to Statement
Duncan Stewart	Bayer	Northern Therapeutics/United Therapeutics	Northern Therapeutics/United Therapeutics	
John Swiston	Bayer, Actelion	Bayer, Novartis, Actelion, Reata, United Therapeutics	None	
Linda Webster	None	Bayer, Bellerophon, United Therapeutics	None	